Emergent BioSolutions | EBS - Ordinary Share Capital


Emergent BioSolutions reported $100K in Ordinary Share Capital for its fiscal quarter ending in June of 2023.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 171.09M 1.9M Mar/2026
Akebia Therapeutics USD 265.42M 199K Dec/2025
ALKERMES USD 167.54M 1.08M Jun/2026
Alnylam Pharmaceuticals USD 133.73M 290K Jun/2026
Amarin USD 20.81M 13K Dec/2025
ANI Pharmaceuticals USD 22.49M 760K Dec/2025
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
Coherus Biosciences USD 121.16M 4.92M Dec/2025
Emergent BioSolutions USD 100K 0 Jun/2023
Exelixis USD 253.7M 8.78M Mar/2026
Glaxosmithkline GBP 4.05B 20.6M Mar/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
Ironwood Pharmaceuticals USD 160K 0 Dec/2024
Lexicon Pharmaceuticals USD 363.47M 67K Dec/2025
Lonza CHF 68.64M 0 Dec/2025
Merck USD 2.47B 4.93M Mar/2026
Moderna USD 391M 2M Sep/2025
Myriad Genetics USD 93.5M 400K Dec/2025
Nektar Therapeutics USD 29.47M 9.09M Mar/2026
Neurocrine Biosciences USD 100.55M 50K Jun/2026
Pacira USD 39.82M 512K Jun/2026
Pfizer USD 5.7B 0 Jun/2026
PTC Therapeutics USD 82.88M 1.41M Mar/2026
Sanofi EUR 1.21B 8.25M Mar/2026
Sarepta Therapeutics USD 105.57M 607K Mar/2026
United Therapeutics USD 42.16M 1.49M Mar/2026
Vanda Pharmaceuticals USD 58K 0 Dec/2024